Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
27
MRK Quote, Financials, Valuation and Earnings
Last price:
$98.47
Seasonality move
:
1.01%
Day range:
$99.24 - $100.35
52-week range:
$94.48 - $134.63
Dividend yield:
3.13%
P/E ratio:
20.90x
P/S ratio:
4.01x
P/B ratio:
5.67x
Volume:
6.1M
Avg. volume:
12.9M
1-year change:
-7.67%
Market cap:
$252.2B
Revenue:
$60.1B
EPS (TTM):
$4.77
Analysts' Opinion
-
Consensus RatingMerck & has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $128.73, Merck & has an estimated upside of 29.11% from its current price of $99.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $100.00 representing 100% downside risk from its current price of $99.70.
Fair Value
-
According to the consensus of 23 analysts, Merck & has 29.11% upside to fair value with a price target of $128.73 per share.
MRK vs. S&P 500
-
Over the past 5 trading days, Merck & has underperformed the S&P 500 by -0.49% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Merck & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Merck & has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Merck & reported revenues of $16.7B.
Earnings Growth
-
Merck & earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Merck & reported earnings per share of $1.24.
Enterprise value:
275.8B
EV / Invested capital:
3.34x
Price / LTM sales:
4.01x
EV / EBIT:
18.42x
EV / Revenue:
4.37x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
18.59x
Price / Operating cash flow:
17.08x
Enterprise value / EBITDA:
14.34x
Gross Profit (TTM):
$47.9B
Return On Assets:
11.06%
Net Income Margin (TTM):
19.23%
Return On Equity:
29.26%
Return On Invested Capital:
15.67%
Operating Margin:
23.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $59B | $59.3B | $63.2B | $16B | $16.7B | |
| Gross Profit | $41.6B | $43.2B | $47.9B | $11.7B | $12.6B | |
| Operating Income | $18.5B | $8.2B | $14.2B | $5.9B | $4B | |
| EBITDA | $21.6B | $12.3B | $19.2B | $7B | $5.6B | |
| Diluted EPS | $6.01 | $1.80 | $4.77 | $1.86 | $1.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.6B | $31.1B | $33.6B | $32B | $40.4B | |
| Total Assets | $89.8B | $93.5B | $107.1B | $106.7B | $117.5B | |
| Current Liabilities | $20.4B | $23.7B | $23B | $23.1B | $29.6B | |
| Total Liabilities | $60.5B | $57.6B | $62.6B | $65.4B | $73B | |
| Total Equity | $29.3B | $35.9B | $44.5B | $41.3B | $44.6B | |
| Total Debt | $28.7B | $26.4B | $30.4B | $34.9B | $38.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $19.7B | $17.2B | $18.3B | $7.7B | $9.3B | |
| Cash From Investing | -$15.3B | -$15.9B | -$6.2B | -$334M | -$3.8B | |
| Cash From Financing | -$2.4B | -$4.1B | -$6.3B | -$4.3B | -$2.4B | |
| Free Cash Flow | $15.2B | $13.2B | $14.8B | $6.8B | $8.5B | |
MRK
Sector
Market Cap
$252.2B
$45.9M
Price % of 52-Week High
74.06%
46.95%
Dividend Yield
3.13%
0%
Shareholder Yield
3.05%
-0.6%
1-Year Price Total Return
-7.67%
-32.15%
Beta (5-Year)
0.393
0.772
Dividend yield:
3.13%
Annualized payout:
$2.96
Payout ratio:
63.72%
Growth streak:
13 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$99.30
200-day SMA
Sell
Level
$117.51
Bollinger Bands (100)
Sell
Level
100.9 - 115.02
Chaikin Money Flow
Buy
Level
757.3M
20-day SMA
Sell
Level
$100.72
Relative Strength Index (RSI14)
Sell
Level
46.37
ADX Line
Buy
Level
23.62
Williams %R
Neutral
Level
-74.0622
50-day SMA
Sell
Level
$101.52
MACD (12, 26)
Sell
Level
-0.72
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
805.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8362)
Sell
CA Score
(Annual)
Level (-0.6378)
Buy
Beneish M-Score
(Annual)
Level (-3.0002)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (19.6764)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Stock Forecast FAQ
In the current month, MRK has received 16 Buy ratings 7 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $128.73.
-
Where Will Merck & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Merck & share price will rise to $128.73 per share over the next 12 months.
-
What Do Analysts Say About Merck &?
Analysts are divided on their view about Merck & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Merck & is a Sell and believe this share price will drop from its current level to $100.00.
-
What Is Merck &'s Price Target?
The price target for Merck & over the next 1-year time period is forecast to be $128.73 according to 23 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is MRK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Merck & is a Buy. 16 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRK?
You can purchase shares of Merck & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Merck & shares.
-
What Is The Merck & Share Price Today?
Merck & was last trading at $98.47 per share. This represents the most recent stock quote for Merck &. Yesterday, Merck & closed at $99.70 per share.
-
How To Buy Merck & Stock Online?
In order to purchase Merck & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 1.62% over the past day.
Sell
50
TSLL alert for Dec 30
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 4.91% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 9.28% over the past day.
